Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 3/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7090447 | 0.90 | PRKDC (0.56) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5065271 | 0.88 | MAPT (0.65) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5058430 | 0.86 | SMN1; SMN2 (0.61) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL18553757 | 0.85 | CCNC (0.53) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5058550 | 0.82 | PRKDC (0.69) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1316711 | 0.82 | PRKDC (0.57) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5063561 | 0.81 | PRKDC (0.62) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5058382 | 0.81 | PRKDC (0.72) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4252909 | 0.81 | HDAC8 (0.76) | MAPTMEN1KMT2AHIF1ASMN1; SMN2 | |
| SCHEMBL5058525 | 0.81 | PRKDC (0.75) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | claimed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| US-8242115-B2 | Inhibit DNA-dependent protein kinase; reduced side effects caused by radiation and chemotherapy drugs | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242115-B2 | Inhibit DNA-dependent protein kinase; reduced side effects caused by radiation and chemotherapy drugs | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242115-B2 | Inhibit DNA-dependent protein kinase; reduced side effects caused by radiation and chemotherapy drugs | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7179912-B2 | Materials and methods to potentiate cancer treatment | ICOS CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179912-B2 | Materials and methods to potentiate cancer treatment | ICOS CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179912-B2 | Materials and methods to potentiate cancer treatment | ICOS CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | PRKDC 17/4885PIK3CD 829/4885PIK3CA 454/4885 |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | PRKDC 17/4885PIK3CD 829/4885PIK3CA 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.